Inhibikase Therapeutics (IKT) Research & Development (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Research & Development for 7 consecutive years, with $430895.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 95.9% year-over-year to $430895.0; the TTM figure through Mar 2026 stood at $12.1 million (down 51.48% YoY), while the FY2025 annual figure was $29.8 million, up 73.11% from the prior year.
• Research & Development retreated to $430895.0 in Q1 2026 per IKT's latest filing, from $6.4 million in the prior quarter.
• Across five years, Research & Development topped out at $13.6 million in Q4 2023 and bottomed at $55114.0 in Q3 2025.
• Historically, Research & Development has averaged $4.5 million across 5 years, with a median of $3.1 million in 2024.
• Annual changes were most pronounced in 2023 — Research & Development jumped 344.91% — and 2025, when it slumped 98.68%.
• Inhibikase Therapeutics' Research & Development stood at $3.1 million in 2022, then jumped by 344.91% to $13.6 million in 2023, then slumped by 47.06% to $7.2 million in 2024, then fell by 11.6% to $6.4 million in 2025, then sank by 93.22% to $430895.0 in 2026.
• Business Quant data shows IKT's Research & Development at $430895.0 in Q1 2026, $6.4 million in Q4 2025, and $55114.0 in Q3 2025.